Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to metformin in type 2 diabetes
NCT00363948Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Placebo (2 arms). Primary endpoints: Hemoglobin A1c at 12 weeks, Safety at 52 weeks and 1 more. Started Aug 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00363948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363948.